<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" xml:lang="EN"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Med Chem</journal-id><journal-id journal-id-type="iso-abbrev">J. Med. Chem</journal-id><journal-id journal-id-type="publisher-id">jm</journal-id><journal-id journal-id-type="coden">jmcmar</journal-id><journal-title-group><journal-title>Journal of Medicinal Chemistry</journal-title></journal-title-group><issn pub-type="ppub">0022-2623</issn><issn pub-type="epub">1520-4804</issn><publisher><publisher-name>American Chemical
Society</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29028171</article-id><article-id pub-id-type="pmc">5682607</article-id><article-id pub-id-type="doi">10.1021/acs.jmedchem.7b01221</article-id><article-categories><subj-group><subject>Article</subject></subj-group></article-categories><title-group><article-title>Structure-Based
Design of Non-natural Macrocyclic
Peptides That Inhibit Protein&#x02013;Protein Interactions</article-title></title-group><contrib-group><contrib contrib-type="author" id="ath1"><name><surname>Kr&#x000fc;ger</surname><given-names>Dennis
M.</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref><xref rid="aff2" ref-type="aff">&#x02021;</xref><xref rid="notes-1" ref-type="notes">&#x000a7;</xref><xref rid="notes-4" ref-type="notes">#</xref></contrib><contrib contrib-type="author" id="ath2"><name><surname>Glas</surname><given-names>Adrian</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref><xref rid="aff2" ref-type="aff">&#x02021;</xref><xref rid="notes-4" ref-type="notes">#</xref></contrib><contrib contrib-type="author" id="ath3"><name><surname>Bier</surname><given-names>David</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref><xref rid="aff3" ref-type="aff">&#x022a5;</xref></contrib><contrib contrib-type="author" id="ath4"><name><surname>Pospiech</surname><given-names>Nicole</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref></contrib><contrib contrib-type="author" id="ath5"><name><surname>Wallraven</surname><given-names>Kerstin</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref></contrib><contrib contrib-type="author" id="ath6"><name><surname>Dietrich</surname><given-names>Laura</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref><xref rid="aff2" ref-type="aff">&#x02021;</xref></contrib><contrib contrib-type="author" id="ath7"><name><surname>Ottmann</surname><given-names>Christian</given-names></name><xref rid="aff3" ref-type="aff">&#x022a5;</xref><xref rid="aff4" ref-type="aff">&#x02225;</xref></contrib><contrib contrib-type="author" corresp="yes" id="ath8"><name><surname>Koch</surname><given-names>Oliver</given-names></name><xref rid="cor1" ref-type="other">*</xref><xref rid="aff2" ref-type="aff">&#x02021;</xref></contrib><contrib contrib-type="author" corresp="yes" id="ath9"><name><surname>Hennig</surname><given-names>Sven</given-names></name><xref rid="cor2" ref-type="other">*</xref><xref rid="aff1" ref-type="aff">&#x02020;</xref><xref rid="aff5" ref-type="aff">&#x02207;</xref></contrib><contrib contrib-type="author" corresp="yes" id="ath10"><name><surname>Grossmann</surname><given-names>Tom N.</given-names></name><xref rid="cor3" ref-type="other">*</xref><xref rid="aff1" ref-type="aff">&#x02020;</xref><xref rid="aff2" ref-type="aff">&#x02021;</xref><xref rid="aff5" ref-type="aff">&#x02207;</xref></contrib><aff id="aff1"><label>&#x02020;</label><institution>Chemical
Genomics Centre of the Max Planck Society</institution>, Otto-Hahn-Str. 15, 44227 Dortmund, <country>Germany</country></aff><aff id="aff2"><label>&#x02021;</label>Faculty
of Chemistry and Chemical Biology, <institution>TU Dortmund
University</institution>, Otto-Hahn-Str.
6, 44227 Dortmund, <country>Germany</country></aff><aff id="aff3"><label>&#x022a5;</label>Department
of Chemistry, <institution>University of Duisburg-Essen</institution>, Universit&#x000e4;tstr. 7, 45141 Essen, <country>Germany</country></aff><aff id="aff4"><label>&#x02225;</label>Department
of Biomedical Engineering, Institute of Complex Molecular Systems, <institution>Eindhoven University of Technology</institution>, Den Dolech 2, 5612 AZ Eindhoven, <country>The Netherlands</country></aff><aff id="aff5"><label>&#x02207;</label>Department
of Chemistry &#x00026; Pharmaceutical Sciences, <institution>VU University Amsterdam</institution>, De Boelelaan 1083, 1081 HV Amsterdam, <country>The Netherlands</country></aff></contrib-group><author-notes><corresp id="cor1"><label>*</label>E-mail: <email>oliver.koch@tu-dortmund.de</email>.</corresp><corresp id="cor2"><label>*</label>E-mail: <email>s.hennig@vu.nl</email>.</corresp><corresp id="cor3"><label>*</label>E-mail: <email>t.n.grossmann@vu.nl</email>.</corresp></author-notes><pub-date pub-type="epub"><day>13</day><month>10</month><year>2017</year></pub-date><pub-date pub-type="ppub"><day>09</day><month>11</month><year>2017</year></pub-date><volume>60</volume><issue>21</issue><fpage>8982</fpage><lpage>8988</lpage><history><date date-type="received"><day>18</day><month>08</month><year>2017</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2017 American Chemical Society</copyright-statement><copyright-year>2017</copyright-year><copyright-holder>American Chemical Society</copyright-holder><license><license-p>This is an open access article published under a Creative Commons Non-Commercial No Derivative Works (CC-BY-NC-ND) Attribution <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/page/policy/authorchoice_ccbyncnd_termsofuse.html">License</ext-link>, which permits copying and redistribution of the article, and creation of adaptations, all for non-commercial purposes.</license-p></license></permissions><abstract><p content-type="toc-graphic"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jm-2017-01221k_0005" id="ab-tgr1"/></p><p>Macrocyclic
peptides can interfere with challenging biomolecular
targets including protein&#x02013;protein interactions. Whereas there
are various approaches that facilitate the identification of peptide-derived
ligands, their evolution into higher affinity binders remains a major
hurdle. We report a virtual screen based on molecular docking that
allows the affinity maturation of macrocyclic peptides taking non-natural
amino acids into consideration. These macrocycles bear large and flexible
substituents that usually complicate the use of docking approaches.
A virtual library containing more than 1400 structures was screened
against the target focusing on docking poses with the core structure
resembling a known bioactive conformation. Based on this screen, a
macrocyclic peptide <bold>22</bold> involving two non-natural amino
acids was evolved showing increased target affinity and biological
activity. Predicted binding modes were verified by X-ray crystallography.
The presented workflow allows the screening of large macrocyclic peptides
with diverse modifications thereby expanding the accessible chemical
space and reducing synthetic efforts.</p></abstract><custom-meta-group><custom-meta><meta-name>document-id-old-9</meta-name><meta-value>jm7b01221</meta-value></custom-meta><custom-meta><meta-name>document-id-new-14</meta-name><meta-value>jm-2017-01221k</meta-value></custom-meta><custom-meta><meta-name>ccc-price</meta-name><meta-value/></custom-meta></custom-meta-group></article-meta></front><body><sec id="sec1"><title>Introduction</title><p>Macrocyclic scaffolds
are a common structural element among natural
products, and they are considered promising candidates for the development
of chemical probes and novel therapeutics.<sup><xref ref-type="bibr" rid="ref1">1</xref>,<xref ref-type="bibr" rid="ref2">2</xref></sup> This
is mainly due to their ability to bind protein surfaces even if those
lack distinct binding pockets. The presence of such pockets is often
required for high affinity binding of classic small molecules.<sup><xref ref-type="bibr" rid="ref3">3</xref>&#x02212;<xref ref-type="bibr" rid="ref5">5</xref></sup> Protein&#x02013;protein interactions (PPIs) tend to involve flat
surfaces rendering their inhibition extremely challenging. Among macrocycles,
peptide-derived structures proved to be particularly valuable starting
points for the generation of PPI inhibitors.<sup><xref ref-type="bibr" rid="ref2">2</xref></sup> Often, the design process starts by macrocyclization of known peptide
binding epitopes,<sup><xref ref-type="bibr" rid="ref2">2</xref></sup> or by the screening
of macrocyclic peptide libraries (e.g., via phage or mRNA display)<sup><xref ref-type="bibr" rid="ref6">6</xref>,<xref ref-type="bibr" rid="ref7">7</xref></sup> resulting in structures that often exhibit good affinity for their
target. However, in most cases an evolution toward higher affinity
ligands is required to efficiently block PPIs and/or to compensate
for affinity losses during the optimization process toward increased
bioavailability.<sup><xref ref-type="bibr" rid="ref2">2</xref></sup> For that reason, affinity
maturation constitutes a bottleneck preventing straightforward use
of bioactive macrocyclic peptides. Ideally, the consideration of numerous
modifications including natural and non-natural amino acids at all
positions of the peptide sequence would be desired.</p><p>Given the
efforts associated with the chemical synthesis and evaluation
of large peptide libraries<sup><xref ref-type="bibr" rid="ref8">8</xref></sup> and the complexity
of biological screening platforms as well as their restriction to
a limited number and type of non-natural building blocks,<sup><xref ref-type="bibr" rid="ref6">6</xref>,<xref ref-type="bibr" rid="ref7">7</xref></sup> computational screening approaches provide an appealing alternative.
In the case of small molecules and short peptide ligands, virtual
screening based on molecular docking has proven particularly useful.<sup><xref ref-type="bibr" rid="ref9">9</xref>&#x02212;<xref ref-type="bibr" rid="ref13">13</xref></sup> For macrocyclic scaffolds with relatively small substituents, benchmark
studies were able to reproduce known binding modes indicating that
docking could also be applied.<sup><xref ref-type="bibr" rid="ref14">14</xref>&#x02212;<xref ref-type="bibr" rid="ref16">16</xref></sup> However, it is not clear if these
approaches allow exhaustive virtual screening and the prediction of
novel interactions as molecular docking encounters severe difficulties
in scoring new binding modes for extended scaffolds.<sup><xref ref-type="bibr" rid="ref12">12</xref>,<xref ref-type="bibr" rid="ref13">13</xref></sup> In particular, the consideration of macrocycles with large and flexible
substituents, as they are often found in peptide-derived PPI inhibitors,<sup><xref ref-type="bibr" rid="ref2">2</xref></sup> can be expected to be extremely challenging.
For this reason, computationally more demanding methods such as molecular
dynamics simulations have been used for protein&#x02013;peptide docking,<sup><xref ref-type="bibr" rid="ref17">17</xref>&#x02212;<xref ref-type="bibr" rid="ref19">19</xref></sup> however, at the cost of a dramatically reduced throughput.<sup><xref ref-type="bibr" rid="ref20">20</xref>&#x02212;<xref ref-type="bibr" rid="ref23">23</xref></sup> An additional challenge in the affinity maturation of macrocyclic
ligands occurs when the starting point already shows good target affinity.<sup><xref ref-type="bibr" rid="ref10">10</xref></sup> In this case, a precise prediction and scoring
of the binding mode is of utmost importance to allow the identification
of improved ligands.<sup><xref ref-type="bibr" rid="ref10">10</xref></sup> The availability
of fast and reliable docking approaches for modified peptide ligands
would accelerate the time-consuming optimization process and is highly
desired.</p><p>Herein, we describe a computational approach based
on molecular
docking that allows the affinity maturation of macrocyclic peptide
ligands. Originally derived from linear bacterial peptide sequence <bold>1</bold> (ESp),<sup><xref ref-type="bibr" rid="ref24">24</xref></sup> macrocyclic peptide <bold>2</bold> (&#x003b2;<sub>ss</sub>12)<sup><xref ref-type="bibr" rid="ref24">24</xref></sup> served
as a starting point. Based on the crystal structure of <bold>2</bold> in complex with its target protein 14&#x02013;3&#x02013;3, a virtual
library of macrocycles was generated, which was screened against the
target. Subsequently, binding poses that resemble the backbone conformation
of the starting peptide in its bound state were scored. This selection
process allowed the identification of a macrocyclic peptide with two
non-natural amino acids, which exhibits increased target affinity
as well as increased potency in cell-based assays. Most importantly,
predicted side chain binding modes were verified by X-ray crystallography.</p></sec><sec id="sec2"><title>Results</title><sec id="sec2.1"><title>Virtual
Peptide Library</title><p>Aiming for a computational
approach that allows the handling of large and flexible structures,
we choose macrocyclic peptide <bold>2</bold> as model system.<sup><xref ref-type="bibr" rid="ref24">24</xref>,<xref ref-type="bibr" rid="ref25">25</xref></sup> This peptide binds 14&#x02013;3&#x02013;3 proteins which form a family
of closely related adaptor proteins that regulates a wide range of
cellular processes via numerous PPIs. Peptide <bold>2</bold> involves
an 11-mer irregularly structured peptide sequence (dark gray, <xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig">1</xref></xref>), which is constrained
by a hydrophobic side chain-to-side chain cross-link in analogy to
so-called hydrocarbon-stapled peptides.<sup><xref ref-type="bibr" rid="ref26">26</xref>,<xref ref-type="bibr" rid="ref27">27</xref></sup> It was originally
derived from the natural peptide epitope <bold>1</bold>.<sup><xref ref-type="bibr" rid="ref24">24</xref></sup> Macrocycle <bold>2</bold> binds to the amphipathic
groove of 14&#x02013;3&#x02013;3, which recognizes certain phosphorylated
proteins and some nonphosphorylated peptide epitopes. Among the synthetic
14&#x02013;3&#x02013;3 binders, macrocyclic peptide <bold>2</bold> is
the highest affinity ligand (<italic>K</italic><sub>d</sub> &#x02248;
0.1 &#x003bc;M).<sup><xref ref-type="bibr" rid="ref24">24</xref>,<xref ref-type="bibr" rid="ref28">28</xref>&#x02212;<xref ref-type="bibr" rid="ref34">34</xref></sup> Its relatively high affinity, molecular weight (M = 1280 g mol<sup>&#x02013;1</sup>) and flexibility render peptide <bold>2</bold> a
challenging starting point for any <italic>in silico</italic> affinity
optimization. The crystal structure of <bold>2</bold> (PDB ID 4n84)<sup><xref ref-type="bibr" rid="ref24">24</xref></sup> in complex with isoform zeta of 14&#x02013;3&#x02013;3 (14&#x02013;3&#x02013;3&#x003b6;)
served as starting point for our work. All following calculations
and biophysical as well as biological experiments were performed with
14&#x02013;3&#x02013;3&#x003b6;.</p><fig id="fig1" position="float"><label>Figure 1</label><caption><p>Sequence of linear peptide <bold>1</bold> and
crystal structure
of cyclic peptide <bold>2</bold> (dark gray) bound to 14&#x02013;3&#x02013;3&#x003b6;
(light gray, PDB ID 4n84). Cross-link and hotspot residues (L426, D427, and L428) are shown
explicitly. Peptide sequence of <bold>2</bold> and chemical structure
of cross-link are shown (Residues are numbered in accordance to PDB
ID 4n84).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jm-2017-01221k_0001" id="gr1" position="float"/></fig><p>Initially, the contribution of
all side chains of peptide <bold>2</bold> to 14&#x02013;3&#x02013;3&#x003b6;
binding was assessed employing
an alanine scan (<xref rid="notes-2" ref-type="notes">Figure S1</xref>). This revealed
three hotspot residues (L426, D427, and L428, <xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig">1</xref></xref>) at which alanine substitution results in
dramatically reduced affinity (&#x0003e;10-fold, <xref rid="notes-2" ref-type="notes">Figure
S1</xref>). Preceding tests reveal that even minor changes at a hotspot
position result in severe affinity reduction (<xref rid="notes-2" ref-type="notes">Figure S2</xref>). We concluded that variation of these residues
is unlikely to result in derivatives with increased binding affinity
and focused on the remaining six amino acids (<xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig">1</xref></xref>). A virtual amino acid library was assembled
(<xref rid="notes-2" ref-type="notes">Table S2</xref>) containing all proteinogenic
amino acids (except for glycine and proline) and 223 nonproteinogenic
ones. These amino acids were selected based on two criteria: (i) commercial
availability of suitably protected analogs allowing a direct use in
solid-phase peptide synthesis (SPPS) and (ii) coverage of a diverse
chemical space preventing the accumulation of closely related derivatives
(<xref rid="notes-2" ref-type="notes">Figure S3</xref>). Incorporation of all amino
acids into the six positions of interest results in a virtual library
of 1446 peptides.</p></sec><sec id="sec2.2"><title>Molecular Docking of Virtual Library</title><p>Given the successful
utilization of molecular docking and scoring approaches for the virtual
screening of small molecules and the achievements with respect to
small peptide ligands,<sup><xref ref-type="bibr" rid="ref9">9</xref>,<xref ref-type="bibr" rid="ref12">12</xref>,<xref ref-type="bibr" rid="ref35">35</xref>,<xref ref-type="bibr" rid="ref36">36</xref></sup> we decided to peruse this strategy. Macrocycle <bold>2</bold> bears large and flexible substituents, features that affect
the validity of docking poses and scoring. To reduce the number of
invalid docking poses, we considered the implementation of a checkpoint
after library docking that would allow focusing on the most relevant
docking poses for subsequent scoring. Knowing the importance of the
three hotspot residues for binding, we reasoned that high affinity
binders will most likely adopt a conformation that positions those
residues in analogy to 14&#x02013;3&#x02013;3-bound <bold>2</bold>.
For that reason, pose filtering was applied, ensuring that only docking
poses were considered for which the central hotspot amino acids (426&#x02013;428)
resemble the conformation of peptide <bold>2</bold> in its bound state
(allowed RMSD &#x02264; 2.0 &#x000c5;). These considerations resulted
in the following workflow in which the crystal structure of peptide <bold>2</bold> in complex with 14&#x02013;3&#x02013;3&#x003b6; (PDB ID 4n84) served as starting
point (for details see <xref rid="notes-2" ref-type="notes">Supporting Information</xref>). First, the coordinates of <bold>2</bold> were extracted, and each
of the six selected residues was iteratively substituted by each member
of the virtual amino acid library (241 building blocks). This resulted
in a database of 1446 macrocyclic peptides each of them bearing a
single residue variation compared to <bold>2</bold>. Second, docking
parameters were adjusted to ensure that the conformation of <bold>2</bold> bound to 14&#x02013;3&#x02013;3 is reproduced upon docking.
These parameters were then used to dock each peptide into the amphipathic
groove of 14&#x02013;3&#x02013;3&#x003b6; using AutoDock Vina<sup><xref ref-type="bibr" rid="ref35">35</xref></sup> to sample the conformational space. Thereafter,
above-mentioned pose filtering was applied followed by a final rescoring
step. For rescoring of docking poses of small peptides, it was shown
to be beneficial to consider a combination of knowledge-based and
empirical scoring functions since they provide complementary hit lists.<sup><xref ref-type="bibr" rid="ref12">12</xref>,<xref ref-type="bibr" rid="ref37">37</xref></sup> In this respect, Astex Statistical Potential<sup><xref ref-type="bibr" rid="ref38">38</xref></sup> (ASP, knowledge-based) and ChemScore<sup><xref ref-type="bibr" rid="ref39">39</xref></sup> (empirical) have been described to be suitable for the
scoring of peptide conformations<sup><xref ref-type="bibr" rid="ref12">12</xref></sup> and
were thus selected for rescoring.<sup><xref ref-type="bibr" rid="ref40">40</xref></sup> For
each peptide, the remaining poses (after pose filtering) were rescored,
and only the highest scoring one was considered for the final ranking.
For each of the six amino acid positions, the top five ranking peptides
per scoring function were visually inspected (in total 60 complexes)
to select one peptide per scoring function (<sup>#</sup>ChemScore, <sup>&#x025ca;</sup>ASP) and position for experimental validation (in total
12 peptides <bold>10</bold>&#x02013;<bold>21</bold>, <xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig">2</xref></xref> and <xref rid="notes-2" ref-type="notes">Figure
S4</xref>).</p><fig id="fig2" position="float"><label>Figure 2</label><caption><p>Chemical structure of <bold>2</bold> with varied residues highlighted
in gray. Selected 12 variations are shown (two per position: one obtained
from ChemScore (#) and the other one from ASP (&#x025ca;) hit list).
Experimentally determined dissociation constants (<italic>K</italic><sub>d</sub>) for corresponding peptides <bold>10</bold>&#x02013;<bold>21</bold> with 14&#x02013;3&#x02013;3&#x003b6; are given (for details
see <xref rid="notes-2" ref-type="notes">Figure S7</xref>). Variations are color coded
in accordance to their affinity for 14&#x02013;3&#x02013;3&#x003b6; (<italic>K</italic><sub>d</sub> rages: dark red, &#x0003c;0.1 &#x003bc;M; light red,
0.1&#x02013;1 &#x003bc;M; white, &#x0003e;1 &#x003bc;M).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jm-2017-01221k_0002" id="gr2" position="float"/></fig></sec><sec id="sec2.3"><title>Experimental Affinities and Structural Validation</title><p>Fluorescently
labeled versions of all 12 peptides were synthesized applying standard
protocols for SPPS and macrocycle formation.<sup><xref ref-type="bibr" rid="ref24">24</xref>,<xref ref-type="bibr" rid="ref41">41</xref></sup> Affinities toward 14&#x02013;3&#x02013;3&#x003b6; (aa 1&#x02013;230)
were determined using a fluorescence polarization (FP) assay. As reference,
the dissociation constant (<italic>K</italic><sub>d</sub>) of <bold>2</bold> was determined (<italic>K</italic><sub>d</sub> = 103 nM).
Among the 12 peptides (<xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig">2</xref></xref>), seven show relatively low affinities for 14&#x02013;3&#x02013;3&#x003b6;
(<italic>K</italic><sub>d</sub> &#x0003e; 1 &#x003bc;M, white) with four
of
them still being in the low micromolar range (6&#x02013;13 &#x003bc;M).
Five peptides exhibit affinities in the submicromolar range (<italic>K</italic><sub>d</sub> &#x0003c; 1 &#x003bc;M, light and dark red) rendering
them better binders than the wildtype epitope <bold>1</bold>. Most
strikingly, among those five peptides, there are two that show lower <italic>K</italic><sub>d</sub> values than starting point <bold>2</bold>.
In one case, leucine at position 423 (L423) is substituted by <sc>l</sc>-(1-adamantyl)glycine (lada, peptide <bold>14</bold>, <italic>K</italic><sub>d</sub> = 59 nM), while in the other one, serine at
position 430 (S430) is substituted by <sc>l</sc>-&#x003b3;-carboxyglutamic
acid (l2ce, peptide <bold>21</bold>, <italic>K</italic><sub>d</sub> = 99 nM). Whereas the non-natural amino acid l2ce in <bold>21</bold> carries a malonic acid side chain predicted to engage a positively
charged cavity on 14&#x02013;3&#x02013;3&#x003b6; (<xref rid="notes-2" ref-type="notes">Figure S5</xref>), lada in <bold>14</bold> bears a bulky and hydrophobic
adamantyl moiety presumably interacting with a hydrophobic patch of
14&#x02013;3&#x02013;3&#x003b6; (<xref rid="notes-2" ref-type="notes">Figure S6</xref>).</p><p>Having identified two variations with increased affinity, we explored
the consequences of incorporating both non-natural amino acids simultaneously
into the sequence resulting in peptide <bold>22</bold> (AdCe). For
a fluorescently labeled version of <bold>22</bold>, 14&#x02013;3&#x02013;3
affinity was determined using FP. Notably, both variations appear
to act additively, resulting in further increased affinity (<italic>K</italic><sub>d</sub> = 38 &#x000b1; 3 nM, <xref rid="notes-2" ref-type="notes">Figure
S7</xref>), which is a 2.7-fold increase compared to starting peptide <bold>2</bold> (103 &#x000b1; 9 nM). To obtain molecular details of the <bold>22</bold>&#x02013;14&#x02013;3&#x02013;3&#x003b6; interaction and to evaluate
the accuracy of our predicted binding modes, we aimed for a crystal
structure of the corresponding complex. Cocrystallization of <bold>22</bold> and 14&#x02013;3&#x02013;3&#x003b6; (aa 1&#x02013;230) provided
crystals of space group <italic>P</italic>2<sub>1</sub>2<sub>1</sub>2<sub>1</sub> and allowed the determination of a crystal structure
with 2.3 &#x000c5; resolution (PDB ID 5jm4, <xref rid="notes-2" ref-type="notes">Table S3</xref>).
Each asymmetric unit contains two 14&#x02013;3&#x02013;3&#x003b6; proteins,
with each harboring one molecule of <bold>22</bold> in its hydrophobic
groove (<xref rid="notes-2" ref-type="notes">Figure S8</xref>). The corresponding 2F<sub>o</sub>&#x02013;F<sub>c</sub> density map (<xref rid="notes-2" ref-type="notes">Figures
S9</xref>) allows the identification of the entire peptide except
for the side chain of N-terminal amino acid Q420, which is not resolved.
Superimposition of <bold>22</bold> (red) and <bold>2</bold> (gray)
in complex with 14&#x02013;3&#x02013;3&#x003b6; (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref>a) reveals good structural overlay (RMSD
backbone: 0.67 &#x000c5;) verifying analogous binding modes. Most importantly,
comparison of the <bold>22</bold> crystal structure with docking predictions
for lada at position 423 (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref>b) and l2ce at position 430 (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref>c) show excellent superimposition. As predicted,
the adamantyl moiety of lada engages a hydrophobic patch of the 14&#x02013;3&#x02013;3&#x003b6;
groove, and the malonate side chain of l2ce interacts with two arginines
of 14&#x02013;3&#x02013;3&#x003b6; (<xref rid="notes-2" ref-type="notes">Figure S10</xref>) that are not addressed by <bold>2</bold>. This accuracy of the
molecular docking is remarkable, considering that the C-terminal part
of the peptide backbone is relatively flexible. Interestingly, lada
at position 423 originates from the ChemScore (#) hit list, while
l2ce at position 430 was suggested after ASP (&#x025ca;) rescoring
(<xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig">2</xref></xref>). This underlines
the usefulness of considering knowledge-based as well as empirical
scoring functions for rescoring.</p><fig id="fig3" position="float"><label>Figure 3</label><caption><p>(a) Overlay of crystal structures of <bold>2</bold> (gray, PDB
ID 4n84) and <bold>22</bold> (red, PDB ID 5jm4) when bound to 14&#x02013;3&#x02013;3&#x003b6; (light
gray surface representation). Peptide backbones are shown as ribbons.
Varied side chains (423 and 430), hotspot residue L428, and cross-link
are shown explicitly. (b,c) Superimposition of <bold>22</bold> crystal
structure (red, PDB ID 5jm4) with predicted structure (orange, pose with highest
score) of lada- and l2ce-modified peptide, respectively. Amino acid
of interest and backbone of neighboring amino acids are shown explicitly.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jm-2017-01221k_0003" id="gr3" position="float"/></fig></sec><sec id="sec2.4"><title>Inhibition of PPI</title><p>Knowing that <bold>22</bold> exhibits
higher affinity for 14&#x02013;3&#x02013;3&#x003b6; than <bold>2</bold> (2.7-fold) and wild-type epitope <bold>1</bold> (20-fold), we were
interested if this results in more efficient competition with PPIs
and increased bioactivity. For that purpose, the competition with
phosphorylated binding partners of 14&#x02013;3&#x02013;3 was considered.
Superimposition of <bold>22</bold> (red) and representative phosphorylated
peptides (blue) in complex with 14&#x02013;3&#x02013;3 shows substantial
overlap (<xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig">4</xref></xref>a),
suggesting competitive binding. To test this hypothesis, we performed
FP competition experiments employing a Raf-derived phosphorylated
peptide ligand (<xref rid="notes-2" ref-type="notes">Figure S12</xref>) of 14&#x02013;3&#x02013;3&#x003b6;
as tracer and nonlabeled peptide <bold>1</bold>, <bold>2</bold>, or <bold>22</bold> as competitor. These measurements (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref>b) clearly show efficient competition of <bold>22</bold> (red) with the phosphorylated peptide (half maximal inhibitory
concentration: IC<sub>50</sub> = 0.8 &#x003bc;M). In line with their
lower affinity, <bold>2</bold> (dark gray, IC<sub>50</sub> = 1.2 &#x003bc;M)
and <bold>1</bold> (light gray, IC<sub>50</sub> = 3.3 &#x003bc;M) exhibit
reduced competition.</p><fig id="fig4" position="float"><label>Figure 4</label><caption><p>(a) Superimposition of <bold>22</bold> (red, PDB ID 5jm4) and selected phosphorylated
peptides (blue, PDB IDs iqja, 1ywt, 2bn5, 2btp, 2c74, 2npm, 2v7d, 3e6y, and 3nkx) bound to 14&#x02013;3&#x02013;3.
Peptide backbones are shown as ribbons and important side chains explicitly.
(b) FP competition using labeled Raf-peptide as tracer (10 nM with
2 &#x003bc;M 14&#x02013;3&#x02013;3) and nonlabeled versions of <bold>1</bold>, <bold>2</bold>, and <bold>22</bold> (including their IC<sub>50</sub> values). (c) Inhibition of <italic>MMP1</italic> transcription
in a cell-based assay after pathway activation with 14&#x02013;3&#x02013;3&#x003b6;
(<italic>c</italic> = 200 nM). Cells were treated for 24 h in the
absence and presence of <bold>1</bold>, <bold>2</bold>, or <bold>22</bold> (20 &#x003bc;M). Expression levels of mRNA were measured by quantitative
real time PCR (for details, see <xref rid="notes-2" ref-type="notes">Supporting Information</xref>).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jm-2017-01221k_0004" id="gr4" position="float"/></fig><p>Finally, it was tested if improved
target affinity also results
in enhanced activity in cell-based assays. Since fluorescence microscopy
indicates very low cellular uptake of these peptides (<xref rid="notes-2" ref-type="notes">Figure S13</xref>), we aimed at the inhibition of an
extracellular 14&#x02013;3&#x02013;3&#x003b6; PPI. It is known that 14&#x02013;3&#x02013;3
proteins bind to the extracellular domain of transmembrane receptor
aminopeptidase N (APN).<sup><xref ref-type="bibr" rid="ref42">42</xref>,<xref ref-type="bibr" rid="ref43">43</xref></sup> This interaction presumably
occurs between phosphorylated epitopes on APN and the amphipathic
groove of 14&#x02013;3&#x02013;3 proteins.<sup><xref ref-type="bibr" rid="ref33">33</xref>,<xref ref-type="bibr" rid="ref44">44</xref></sup> It is known that APN&#x02013;14&#x02013;3&#x02013;3 complex formation
induces an intracellular signaling cascade, triggering the expression
of a subset of matrix metalloproteinases (MMPs),<sup><xref ref-type="bibr" rid="ref42">42</xref>,<xref ref-type="bibr" rid="ref43">43</xref></sup> and that the inhibition of extracellular 14&#x02013;3&#x02013;3 can
reduce MMP transcription levels.<sup><xref ref-type="bibr" rid="ref33">33</xref></sup> MMPs
are important factors in the modulation of the extracellular matrix,
and their upregulation is associated with pathological processes such
as rheumatoid arthritis or cancer metastasis.<sup><xref ref-type="bibr" rid="ref45">45</xref>&#x02212;<xref ref-type="bibr" rid="ref47">47</xref></sup> For that reason,
MMP inhibition is considered an attractive therapeutic approach. To
investigate the potency of <bold>22</bold> in MMP inhibition, we used
U87 glioblastoma cells showing robust upregulation of <italic>MMP1</italic> mRNA levels (<italic>R</italic><sub>q</sub> = 11.7, <xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig">4</xref></xref>c) upon treatment with 14&#x02013;3&#x02013;3&#x003b6;
(<italic>c</italic> = 200 nM). After incubation with a nonlabeled
version of <bold>22</bold> (<italic>c</italic> = 20 &#x003bc;M), 14&#x02013;3&#x02013;3&#x003b6;-dependent
increase of <italic>MMP1</italic> mRNA was drastically reduced (8.6-fold
reduction, relative to untreated cells) restoring the levels of nonstimulated
cells. Concentration-dependent treatments provide an IC<sub>50</sub> value of 8.6 &#x003bc;M for <bold>22</bold> (<xref rid="notes-2" ref-type="notes">Figure
S14</xref>), which exceeds the potency of any synthetic competitive
inhibitor reported so far.<sup><xref ref-type="bibr" rid="ref24">24</xref>,<xref ref-type="bibr" rid="ref28">28</xref>&#x02212;<xref ref-type="bibr" rid="ref34">34</xref></sup> Compared to <bold>22</bold> (8.6-fold reduction), the nonlabeled
versions of <bold>1</bold> and <bold>2</bold> show significantly reduced
inhibition of <italic>MMP1</italic> transcription (1.6- and 3.0-fold
reduction, respectively).</p></sec></sec><sec id="sec3"><title>Discussion and Conclusions</title><p>In conclusion, we report a fast molecular docking approach that
allows the affinity maturation of medium-sized modified peptides considering
natural and non-natural amino acid variations. The combination of
virtual library screening and peptide-adapted molecular docking resulted
in a short hit list enriched with 14&#x02013;3&#x02013;3&#x003b6; binders
allowing to lower experimental validation efforts dramatically. We
utilized a fast molecular docking approach by focusing only on generated
binding poses that locate the three hot spot residues at their original
positions. As a result, the bound conformation of the core structure
is preserved while keeping the termini of the peptide flexible. For
the first time, virtual screening of a large macrocyclic peptide library
was successfully applied while omitting the use of time-consuming
computational approaches. Notably, the 12 single residue variations
(selected from a database of 1446 peptides) contain five hits with
submicromolar affinities, which can be useful in the future to improve,
e.g., physicochemical properties. The combination of the two highest
affinity variations, a hydrophobic and a hydrophilic non-natural amino
acid, allowed the design of a peptide with ca. 3-fold increased affinity
for 14&#x02013;3&#x02013;3&#x003b6;. Most importantly, predicted binding
modes of these novel side chains were verified by X-ray crystallography
underlining the validity of the docking results. The finally evolved
macrocyclic PPI inhibitor shows increased potency in PPI inhibition
and in a cell-based assay. Our computational workflow allows the use
of very large databases of non-natural amino acids, e.g., created
by <italic>in silico</italic> methods. Taking into account the broad
chemical space accessible with such libraries, it is an appealing
strategy for the development of novel peptide-based inhibitors.</p></sec><sec id="sec4"><title>Experimental Section</title><sec id="sec4.1"><title>General</title><p>For detailed
information about experimental
procedures, see the <xref rid="notes-2" ref-type="notes">Supporting Information</xref>. Peptide synthesis was performed on solid support following standard
Fmoc-based protocols with macrocyclization and double-bond reduction
following previously published procedures.<sup><xref ref-type="bibr" rid="ref41">41</xref></sup> Peptide purity was determined by RP-HPLC via peak integration at
&#x003bb; = 210 nm. All peptides exhibit a purity &#x02265;95%. Expression
and purification of 14&#x02013;3&#x02013;3&#x003b6; (aa 1&#x02013;230)
was performed according to established protocols.<sup><xref ref-type="bibr" rid="ref24">24</xref></sup></p></sec><sec id="sec4.2"><title>Structure and Library Preparation for Docking</title><p>Coordinates
from protein&#x02013;ligand complex were retrieved from PDB entry 4n84. Water molecules
and ions were removed. AutoDock-Tools (ADT) 1.5.6 was used to add
polar hydrogens and charges.<sup><xref ref-type="bibr" rid="ref48">48</xref></sup> For peptides,
rotatable bonds were assigned (all substituents including the two
peptide sequences were kept flexible except for amide bonds). Two-dimensional
structures of the 18 natural (Gly and Pro are excluded) and 223 nonproteinogenic
amino acids were manually created using ChemDraw 14.0 and subsequently
converted to 3D structures in protonation states under neutral condition
using Maestro 9.3.5.<sup><xref ref-type="bibr" rid="ref49">49</xref></sup> The peptide library
was created using in-house Python scripts by replacing single amino
acids of <bold>2</bold> with each amino acid in the amino acid library.</p></sec><sec id="sec4.3"><title>Docking Engine, Scoring Function, and Docking Experiments</title><p>AutoDock Vina 1.1.2 was used as a docking engine.<sup><xref ref-type="bibr" rid="ref35">35</xref></sup> The center of the grid box was set to 10/13/10, and the
box size was set to 30 &#x000c5; in each dimension. Docking parameters
were chosen as follows: exhaustiveness = 12, weight_gauss1 = 0.7,
weight_repulsion = 0.5, weight_hydrophobic = &#x02212;0.15, weight_hydrogen
= &#x02212;0.6. (other parameters default). During pose filtering,
all poses were excluded in which the functional groups of residues
L426, D427, and L428 exhibit an rmsd &#x0003e; 2 &#x000c5; when compared to
analog
residues in <bold>2</bold> bound to 14&#x02013;3&#x02013;3 (PDB ID 4n84). For rescoring,
the remaining poses were scored with ChemScore<sup><xref ref-type="bibr" rid="ref39">39</xref></sup> and the Astex statistical potential (ASP),<sup><xref ref-type="bibr" rid="ref38">38</xref></sup> respectively, using the simplex minimization option as
implemented in Gold 5.2.2.4.<sup><xref ref-type="bibr" rid="ref40">40</xref></sup> For each
peptide, only the highest scoring pose was considered for the final
ranking. The top five ranking peptides per scoring function and position
were visually inspected (in total 60 complexes) to select one peptide
per scoring function and position for experimental validation (in
total 12 peptides). For selected peptides and their predicted binding
modes, see <xref rid="notes-2" ref-type="notes">Supplementary Figure S4</xref>.</p></sec><sec id="sec4.4"><title>Fluorescence
Polarization Assays</title><p>A 0.1 mM solution
of the corresponding FITC-labeled peptide in DMSO was diluted with
FP buffer (10 mM HEPES, 150 mM NaCl, 0.1% Tween-20, pH 7.4) to 40
nM. 14&#x02212;3&#x02013;3&#x003b6; (aa 1&#x02013;230) was diluted with
FP buffer in a 2.5-fold dilution series (80 &#x003bc;M&#x02013;0.5 nM)
in a 384-well plate. To 15 &#x003bc;L of the protein solution, 5 &#x003bc;L
of the 40 nM peptide stock was added (final peptide concentration,
10 nM; final protein concentrations, 60 &#x003bc;M&#x02013;0.4 nM). After
1 h, fluorescence polarization was measured (&#x003bb;(ex) = 485 nm;
&#x003bb;(em) = 525 nm). The dissociation constant (<italic>K</italic><sub>d</sub>) was determined from the binding curve with GraphPad
from Prism. For competition experiments, N-terminally acetylated peptides
were diluted 1:1 in a 384-well plate (10 &#x003bc;L, 100 &#x003bc;M&#x02013;1
nM). 10 &#x003bc;L of a mixture (1:1) of 14&#x02013;3&#x02013;3&#x003b6;
(aa 1&#x02013;230) and TAMRA-labeled cRaf peptide was added (final
concentrations: acetylated peptides = 50 &#x003bc;M&#x02013;0.5 nM; 14&#x02013;3&#x02013;3&#x003b6;
(aa 1&#x02013;230) = 800 nM; TAMRA-labeled cRaf peptide = 100 nM).
After 1 h, fluorescence polarization was measured (&#x003bb;(ex) = 530
nm; &#x003bb;(em) = 585 nm). The half maximal inhibitory concentration
(IC<sub>50</sub>) was determined from the binding curve with GraphPad
from Prism.</p></sec><sec id="sec4.5"><title>X-ray Crystallography and Structure Determination</title><p>14&#x02013;3&#x02013;3&#x003b6;
(aa 1&#x02013;230) was prepared in 50 mM HEPES (pH 7.5), 100 mM NaCl,
and 2 mM MgCl<sub>2</sub>. For complexation, <bold>22</bold> was dissolved
in DMSO (11 mM) and mixed with the protein in a molar ratio of 1:2
(protein/peptide). The complex was incubated overnight at 4 &#x000b0;C
(final protein concentration: 22 mg/mL) and set up for crystallization
using NeXtal Screens (Qiagen). Crystals grew within 4 weeks in the
following condition: 1.36 M sodium citrate and 15% (v/v) glycerol
and showed a diffraction to 2.34 &#x000c5;. After molecular replacement,
the space group was determined to be <italic>P</italic>2<sub>1</sub>2<sub>1</sub>2<sub>1</sub>. Data was collected using PXII beamline
for protein crystallography at the Paul Scherrer Institute Swiss Light
Source (SLS). Crystallographic analysis was performed using the XDS
software package. Molecular replacement was carried out with the CCP4
package, and model building was performed with COOT (<xref rid="notes-2" ref-type="notes">Supplementary Table 3</xref>). Crystal structure was deposited in
the Protein Data Bank (PDB: 5jm4).</p></sec><sec id="sec4.6"><title>Cell Permeability Assay</title><p>HeLa cells
were grown as a
monolayer in 10 cm tissue culture dishes and cultured in DMEM supplemented
with 10% fetal calf serum, and nonessential amino acids (at 37 &#x000b0;C
in an atmosphere of 5% CO<sub>2</sub>). For experiments, cells were
removed from flasks by treatment with trypsin-EDTA, and 5000 cells
were plated in each well of a 96-well microplate and cultured for
24 h. Then, peptides were added at a final concentration of 20 &#x003bc;M
with 1% DMSO to the medium and incubated for 4 h. Cells were washed
three times with PBS, fixed with 4% paraformaldehyde, and washed another
three times with PBS. For nuclear staining, a 3 &#x003bc;M 4&#x02032;,6-diamidino-2-phenylindole
(DAPI) solution in PBS was prepared and left on the cells for at least
5 min. After additional washing steps, the cells were left in PBS,
and the distribution of FITC-labeled peptides was analyzed via fluorescence
microscopy using a 20&#x000d7; air objective (Axiovert 40 CFL, Zeiss).</p></sec><sec id="sec4.7"><title>Quantitative Real Time PCR Analysis</title><p>U87 glioblastoma
cells were cultivated in DMEM (+10% FCS) at 37 &#x000b0;C at 5% CO<sub>2</sub>. Cells were plated for 24 h, and medium was changed (DMEM
+ 1% FCS). After another 24 h, cells were treated with 200 nM 14&#x02013;3&#x02013;3&#x003b6;,
the corresponding peptides in DMEM + 1% FCS and 0.5% DMSO. Untreated
and 14&#x02013;3&#x02013;3&#x003b6;-treated controls were cultivated under
the same conditions with 0.5% DMSO. After 24 h of incubation, total
RNA was isolated (Quick-RNA MicroPrep Kit, Zymo Research) and reverse
transcribed into cDNA (Quanti Tect Reverse Transcription Kit, Qiagen).
Next, cDNA was used for quantitative real time PCR (SensiMix SYBR
Low-ROX Kit, Bioline) in the Applied Biosystems 7500 Fast Real Time
PCR machine (Thermo Fisher Scientific). For relative quantitation,
2<sup>&#x02212;&#x00394;&#x00394;CT</sup> method was used with the reference
gene GAPDH.</p></sec></sec></body><back><notes id="notes-2" notes-type="si"><title>Supporting Information Available</title><p>The Supporting Information
is available free of charge on the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org">ACS Publications website</ext-link> at DOI: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/abs/10.1021/acs.jmedchem.7b01221">10.1021/acs.jmedchem.7b01221</ext-link>.<list id="silist" list-type="simple"><list-item><p>Computational
setup, peptide synthesis and characterization,
protein expression and purification, fluorescence polarization assays,
X-ray crystallography and structure determination, cell permeability
assay, quantitative real time PCR analysis (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.7b01221/suppl_file/jm7b01221_si_001.pdf">PDF</ext-link>)</p></list-item><list-item><p>Highest scored binding mode of <bold>10</bold>&#x02212;<bold>21</bold> (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.7b01221/suppl_file/jm7b01221_si_002.zip">ZIP</ext-link>)</p></list-item><list-item><p>Molecular formula strings of peptides (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.7b01221/suppl_file/jm7b01221_si_003.csv">CSV</ext-link>)</p></list-item></list></p></notes><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="sifile1"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jm7b01221_si_001.pdf"><caption><p>jm7b01221_si_001.pdf</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="sifile2"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jm7b01221_si_002.zip"><caption><p>jm7b01221_si_002.zip</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="sifile3"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jm7b01221_si_003.csv"><caption><p>jm7b01221_si_003.csv</p></caption></media></supplementary-material></sec><notes notes-type="accession-codes" id="notes-3"><title>Accession Codes</title><p>Crystal structure
of <bold>22</bold> in complex with 14&#x02013;3&#x02013;3 has been released
as PDB ID 5jm4.</p></notes><notes notes-type="" id="notes-1"><title>Author Present Address</title><p><sup>&#x000a7;</sup> Department
of Cell and Molecular Biology, Uppsala University, BMC
Box 596, 751 24 Uppsala, Sweden.</p></notes><notes notes-type="" id="notes-4"><title>Author Contributions</title><p><sup>#</sup> These authors
contributed equally to this work.</p></notes><notes notes-type="COI-statement" id="notes-5"><p>The authors
declare no competing financial interest.</p></notes><ack><title>Acknowledgments</title><p>We are
grateful for support from AstraZeneca, Bayer CropScience,
Bayer HealthCare, Boehringer Ingelheim, Merck KGaA, and the Max-Planck-Society.
O.K. is funded by the German Federal Ministry for Education and Research
(Medizinische Chemie in Dortmund, Grant No. BMBF 1316053). T.N.G.
thanks the Deutsche Forschungsgemeinschaft (DFG; Emmy Noether program
GR3592/2-1) and the European Reasearch Council (ERC; ERC starting
grant, no. 678623). This work was supported by the Collaborative Research
Centre 1093, funded by the Deutsche Forschungsgemeinschaft (DFG).
We appreciate IT support by C. Schwittek (MPI Dortmund).</p></ack><glossary id="dl2"><def-list><title>Abbreviations Used</title><def-item><term>ACN</term><def><p>acetonitrile</p></def></def-item><def-item><term>ADT</term><def><p>AutoDock-Tools</p></def></def-item><def-item><term>APN</term><def><p>aminopeptidase
N, CD13</p></def></def-item><def-item><term>ASP</term><def><p>Astex
Statistical Potential</p></def></def-item><def-item><term>cRAF</term><def><p>RAF proto-oncogene
serine/threonine-protein kinase</p></def></def-item><def-item><term>DAP</term><def><p>4&#x02032;,6-diamidino-2-phenylindole</p></def></def-item><def-item><term>DIPEA</term><def><p><italic>N</italic>,<italic>N</italic>-diisopropylethylamine</p></def></def-item><def-item><term>DMEM</term><def><p>Dulbecco&#x02019;s modified Eagle&#x02019;s medium</p></def></def-item><def-item><term>EDT</term><def><p>1,2-ethanedithiol</p></def></def-item><def-item><term>FCS</term><def><p>fetal calf serum</p></def></def-item><def-item><term>FITC</term><def><p>fluorescein isothiocyanate</p></def></def-item><def-item><term>FP</term><def><p>fluorescence polarization</p></def></def-item><def-item><term>GAPDH</term><def><p>glyceraldehyde-3-phosphate
dehydrogenase</p></def></def-item><def-item><term>HEPES</term><def><p>4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid</p></def></def-item><def-item><term>IPTG</term><def><p>isopropyl-&#x003b2;-<sc>d</sc>-1-thiogalactopyranoside</p></def></def-item><def-item><term><italic>K</italic><sub>d</sub></term><def><p>dissociation constant (M)</p></def></def-item><def-item><term>MMP</term><def><p>matrix metalloproteinase</p></def></def-item><def-item><term>NTA</term><def><p>nickelnitrilotriacetic acid</p></def></def-item><def-item><term>PEG<sub>2</sub></term><def><p>8-amino-3,6-dioxaoctanoyl</p></def></def-item><def-item><term>PPI</term><def><p>protein&#x02013;protein
interaction</p></def></def-item><def-item><term>PyBop</term><def><p>(benzotriazol-1-yloxy)tripyrrolidinophosphonium hexafluorophosphate</p></def></def-item><def-item><term>SASA</term><def><p>solvent accessible
surface area</p></def></def-item><def-item><term>SEC</term><def><p>size exclusion chromatography</p></def></def-item><def-item><term>SLS</term><def><p>swiss light source</p></def></def-item><def-item><term>SPPS</term><def><p>solid phase peptide synthesis</p></def></def-item><def-item><term>TAMRA</term><def><p>5-carboxytetramethylrhodamine</p></def></def-item><def-item><term>TCEP</term><def><p>tris(2-carboxyethyl)phosphine</p></def></def-item><def-item><term>TEV</term><def><p>tobacco etch virus</p></def></def-item></def-list></glossary><ref-list><title>References</title><ref id="ref1"><mixed-citation publication-type="journal" id="cit1"><name><surname>Villar</surname><given-names>E. A.</given-names></name>; <name><surname>Beglov</surname><given-names>D.</given-names></name>; <name><surname>Chennamadhavuni</surname><given-names>S.</given-names></name>; <name><surname>Porco</surname><given-names>J. A.</given-names><suffix>Jr.</suffix></name>; <name><surname>Kozakov</surname><given-names>D.</given-names></name>; <name><surname>Vajda</surname><given-names>S.</given-names></name>; <name><surname>Whitty</surname><given-names>A.</given-names></name>
<article-title>How proteins bind macrocycles</article-title>. <source>Nat. Chem. Biol.</source>
<year>2014</year>, <volume>10</volume> (<issue>9</issue>), <fpage>723</fpage>&#x02013;<lpage>731</lpage>. <pub-id pub-id-type="doi">10.1038/nchembio.1584</pub-id>.<pub-id pub-id-type="pmid">25038790</pub-id></mixed-citation></ref><ref id="ref2"><mixed-citation publication-type="journal" id="cit2"><name><surname>Pelay-Gimeno</surname><given-names>M.</given-names></name>; <name><surname>Glas</surname><given-names>A.</given-names></name>; <name><surname>Koch</surname><given-names>O.</given-names></name>; <name><surname>Grossmann</surname><given-names>T. N.</given-names></name>
<article-title>Structure-based
design of inhibitors of protein-protein interactions: mimicking peptide
binding epitopes</article-title>. <source>Angew. Chem., Int. Ed.</source>
<year>2015</year>, <volume>54</volume> (<issue>31</issue>), <fpage>8896</fpage>&#x02013;<lpage>8927</lpage>. <pub-id pub-id-type="doi">10.1002/anie.201412070</pub-id>.</mixed-citation></ref><ref id="ref3"><mixed-citation publication-type="journal" id="cit3"><name><surname>Sperandio</surname><given-names>O.</given-names></name>; <name><surname>Reynes</surname><given-names>C. H.</given-names></name>; <name><surname>Camproux</surname><given-names>A.-C.</given-names></name>; <name><surname>Villoutreix</surname><given-names>B. O.</given-names></name>
<article-title>Rationalizing
the chemical space of protein-protein interaction inhibitors</article-title>. <source>Drug Discovery Today</source>
<year>2010</year>, <volume>15</volume> (<issue>5&#x02013;6</issue>), <fpage>220</fpage>&#x02013;<lpage>229</lpage>. <pub-id pub-id-type="doi">10.1016/j.drudis.2009.11.007</pub-id>.<pub-id pub-id-type="pmid">19969101</pub-id></mixed-citation></ref><ref id="ref4"><mixed-citation publication-type="journal" id="cit4"><name><surname>Nevola</surname><given-names>L.</given-names></name>; <name><surname>Giralt</surname><given-names>E.</given-names></name>
<article-title>Modulating protein-protein
interactions: the potential
of peptides</article-title>. <source>Chem. Commun.</source>
<year>2015</year>, <volume>51</volume> (<issue>16</issue>), <fpage>3302</fpage>&#x02013;<lpage>3315</lpage>. <pub-id pub-id-type="doi">10.1039/C4CC08565E</pub-id>.</mixed-citation></ref><ref id="ref5"><mixed-citation publication-type="journal" id="cit5"><name><surname>Milroy</surname><given-names>L. G.</given-names></name>; <name><surname>Grossmann</surname><given-names>T. N.</given-names></name>; <name><surname>Hennig</surname><given-names>S.</given-names></name>; <name><surname>Brunsveld</surname><given-names>L.</given-names></name>; <name><surname>Ottmann</surname><given-names>C.</given-names></name>
<article-title>Modulators of protein-protein
interactions</article-title>. <source>Chem. Rev.</source>
<year>2014</year>, <volume>114</volume> (<issue>9</issue>), <fpage>4695</fpage>&#x02013;<lpage>4748</lpage>. <pub-id pub-id-type="doi">10.1021/cr400698c</pub-id>.<pub-id pub-id-type="pmid">24735440</pub-id></mixed-citation></ref><ref id="ref6"><mixed-citation publication-type="journal" id="cit6"><name><surname>Passioura</surname><given-names>T.</given-names></name>; <name><surname>Katoh</surname><given-names>T.</given-names></name>; <name><surname>Goto</surname><given-names>Y.</given-names></name>; <name><surname>Suga</surname><given-names>H.</given-names></name>
<article-title>Selection-based discovery
of druglike macrocyclic peptides</article-title>. <source>Annu. Rev.
Biochem.</source>
<year>2014</year>, <volume>83</volume>, <fpage>727</fpage>&#x02013;<lpage>752</lpage>. <pub-id pub-id-type="doi">10.1146/annurev-biochem-060713-035456</pub-id>.<pub-id pub-id-type="pmid">24580641</pub-id></mixed-citation></ref><ref id="ref7"><mixed-citation publication-type="journal" id="cit7"><name><surname>Heinis</surname><given-names>C.</given-names></name>; <name><surname>Winter</surname><given-names>G.</given-names></name>
<article-title>Encoded libraries of chemically modified peptides</article-title>. <source>Curr. Opin. Chem. Biol.</source>
<year>2015</year>, <volume>26</volume>, <fpage>89</fpage>&#x02013;<lpage>98</lpage>. <pub-id pub-id-type="doi">10.1016/j.cbpa.2015.02.008</pub-id>.<pub-id pub-id-type="pmid">25768886</pub-id></mixed-citation></ref><ref id="ref8"><mixed-citation publication-type="journal" id="cit8"><name><surname>Rezaei
Araghi</surname><given-names>R.</given-names></name>; <name><surname>Ryan</surname><given-names>J. A.</given-names></name>; <name><surname>Letai</surname><given-names>A.</given-names></name>; <name><surname>Keating</surname><given-names>A. E.</given-names></name>
<article-title>Rapid Optimization
of Mcl-1 inhibitors using stapled peptide libraries including non-natural
side chains</article-title>. <source>ACS Chem. Biol.</source>
<year>2016</year>, <volume>11</volume> (<issue>5</issue>), <fpage>1238</fpage>&#x02013;<lpage>1244</lpage>. <pub-id pub-id-type="doi">10.1021/acschembio.5b01002</pub-id>.<pub-id pub-id-type="pmid">26854535</pub-id></mixed-citation></ref><ref id="ref9"><mixed-citation publication-type="journal" id="cit9"><name><surname>Falchi</surname><given-names>F.</given-names></name>; <name><surname>Caporuscio</surname><given-names>F.</given-names></name>; <name><surname>Recanatini</surname><given-names>M.</given-names></name>
<article-title>Structure-based design of small-molecule
protein-protein interaction modulators: the story so far</article-title>. <source>Future Med. Chem.</source>
<year>2014</year>, <volume>6</volume> (<issue>3</issue>), <fpage>343</fpage>&#x02013;<lpage>357</lpage>. <pub-id pub-id-type="doi">10.4155/fmc.13.204</pub-id>.<pub-id pub-id-type="pmid">24575969</pub-id></mixed-citation></ref><ref id="ref10"><mixed-citation publication-type="journal" id="cit10"><name><surname>Scott</surname><given-names>D. E.</given-names></name>; <name><surname>Bayly</surname><given-names>A. R.</given-names></name>; <name><surname>Abell</surname><given-names>C.</given-names></name>; <name><surname>Skidmore</surname><given-names>J.</given-names></name>
<article-title>Small molecules, big
targets: drug discovery faces the protein-protein interaction challenge</article-title>. <source>Nat. Rev. Drug Discovery</source>
<year>2016</year>, <volume>15</volume> (<issue>8</issue>), <fpage>533</fpage>&#x02013;<lpage>550</lpage>. <pub-id pub-id-type="doi">10.1038/nrd.2016.29</pub-id>.<pub-id pub-id-type="pmid">27050677</pub-id></mixed-citation></ref><ref id="ref11"><mixed-citation publication-type="journal" id="cit11"><name><surname>Kruger</surname><given-names>D. M.</given-names></name>; <name><surname>Jessen</surname><given-names>G.</given-names></name>; <name><surname>Gohlke</surname><given-names>H.</given-names></name>
<article-title>How good are
state-of-the-art docking
tools in predicting ligand binding modes in protein-protein interfaces?</article-title>. <source>J. Chem. Inf. Model.</source>
<year>2012</year>, <volume>52</volume> (<issue>11</issue>), <fpage>2807</fpage>&#x02013;<lpage>2811</lpage>. <pub-id pub-id-type="doi">10.1021/ci3003599</pub-id>.<pub-id pub-id-type="pmid">23072688</pub-id></mixed-citation></ref><ref id="ref12"><mixed-citation publication-type="journal" id="cit12"><name><surname>Hauser</surname><given-names>A. S.</given-names></name>; <name><surname>Windshugel</surname><given-names>B.</given-names></name>
<article-title>LEADS-PEP:
A benchmark data set for assessment of peptide
docking performance</article-title>. <source>J. Chem. Inf. Model.</source>
<year>2016</year>, <volume>56</volume> (<issue>1</issue>), <fpage>188</fpage>&#x02013;<lpage>200</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jcim.5b00234</pub-id>.<pub-id pub-id-type="pmid">26651532</pub-id></mixed-citation></ref><ref id="ref13"><mixed-citation publication-type="journal" id="cit13"><name><surname>Rentzsch</surname><given-names>R.</given-names></name>; <name><surname>Renard</surname><given-names>B. Y.</given-names></name>
<article-title>Docking small peptides remains a great challenge: an
assessment using AutoDock Vina</article-title>. <source>Briefings Bioinf.</source>
<year>2015</year>, <volume>16</volume> (<issue>6</issue>), <fpage>1045</fpage>&#x02013;<lpage>1056</lpage>. <pub-id pub-id-type="doi">10.1093/bib/bbv008</pub-id>.</mixed-citation></ref><ref id="ref14"><mixed-citation publication-type="journal" id="cit14"><name><surname>Alogheli</surname><given-names>H.</given-names></name>; <name><surname>Olanders</surname><given-names>G.</given-names></name>; <name><surname>Schaal</surname><given-names>W.</given-names></name>; <name><surname>Brandt</surname><given-names>P.</given-names></name>; <name><surname>Karlen</surname><given-names>A.</given-names></name>
<article-title>Docking of
macrocycles: comparing rigid and flexible docking in glide</article-title>. <source>J. Chem. Inf. Model.</source>
<year>2017</year>, <volume>57</volume> (<issue>2</issue>), <fpage>190</fpage>&#x02013;<lpage>202</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jcim.6b00443</pub-id>.<pub-id pub-id-type="pmid">28079375</pub-id></mixed-citation></ref><ref id="ref15"><mixed-citation publication-type="journal" id="cit15"><name><surname>Anighoro</surname><given-names>A.</given-names></name>; <name><surname>de la Vega de Leon</surname><given-names>A.</given-names></name>; <name><surname>Bajorath</surname><given-names>J.</given-names></name>
<article-title>Predicting bioactive conformations
and binding modes of macrocycles</article-title>. <source>J. Comput.-Aided
Mol. Des.</source>
<year>2016</year>, <volume>30</volume> (<issue>10</issue>), <fpage>841</fpage>&#x02013;<lpage>849</lpage>. <pub-id pub-id-type="doi">10.1007/s10822-016-9973-5</pub-id>.<pub-id pub-id-type="pmid">27655412</pub-id></mixed-citation></ref><ref id="ref16"><mixed-citation publication-type="journal" id="cit16"><name><surname>Hochscherf</surname><given-names>J.</given-names></name>; <name><surname>Lindenblatt</surname><given-names>D.</given-names></name>; <name><surname>Steinkruger</surname><given-names>M.</given-names></name>; <name><surname>Yoo</surname><given-names>E.</given-names></name>; <name><surname>Ulucan</surname><given-names>O.</given-names></name>; <name><surname>Herzig</surname><given-names>S.</given-names></name>; <name><surname>Issinger</surname><given-names>O. G.</given-names></name>; <name><surname>Helms</surname><given-names>V.</given-names></name>; <name><surname>Gotz</surname><given-names>C.</given-names></name>; <name><surname>Neundorf</surname><given-names>I.</given-names></name>; <name><surname>Niefind</surname><given-names>K.</given-names></name>; <name><surname>Pietsch</surname><given-names>M.</given-names></name>
<article-title>Development
of a high-throughput
screening-compatible assay to identify inhibitors of the CK2 alpha/CK2
beta interaction</article-title>. <source>Anal. Biochem.</source>
<year>2015</year>, <volume>468</volume>, <fpage>4</fpage>&#x02013;<lpage>14</lpage>. <pub-id pub-id-type="doi">10.1016/j.ab.2014.09.003</pub-id>.<pub-id pub-id-type="pmid">25233003</pub-id></mixed-citation></ref><ref id="ref17"><mixed-citation publication-type="journal" id="cit17"><name><surname>Antes</surname><given-names>I.</given-names></name>
<article-title>DynaDock:
A new molecular dynamics-based algorithm for protein-peptide docking
including receptor flexibility</article-title>. <source>Proteins: Struct.,
Funct., Genet.</source>
<year>2010</year>, <volume>78</volume> (<issue>5</issue>), <fpage>1084</fpage>&#x02013;<lpage>1104</lpage>. <pub-id pub-id-type="doi">10.1002/prot.22629</pub-id>.<pub-id pub-id-type="pmid">20017216</pub-id></mixed-citation></ref><ref id="ref18"><mixed-citation publication-type="journal" id="cit18"><name><surname>Dagliyan</surname><given-names>O.</given-names></name>; <name><surname>Proctor</surname><given-names>E. A.</given-names></name>; <name><surname>D&#x02019;Auria</surname><given-names>K. M.</given-names></name>; <name><surname>Ding</surname><given-names>F.</given-names></name>; <name><surname>Dokholyan</surname><given-names>N. V.</given-names></name>
<article-title>Structural
and dynamic determinants of protein-peptide recognition</article-title>. <source>Structure</source>
<year>2011</year>, <volume>19</volume> (<issue>12</issue>), <fpage>1837</fpage>&#x02013;<lpage>1845</lpage>. <pub-id pub-id-type="doi">10.1016/j.str.2011.09.014</pub-id>.<pub-id pub-id-type="pmid">22153506</pub-id></mixed-citation></ref><ref id="ref19"><mixed-citation publication-type="journal" id="cit19"><name><surname>Ciemny</surname><given-names>M. P.</given-names></name>; <name><surname>Debinski</surname><given-names>A.</given-names></name>; <name><surname>Paczkowska</surname><given-names>M.</given-names></name>; <name><surname>Kolinski</surname><given-names>A.</given-names></name>; <name><surname>Kurcinski</surname><given-names>M.</given-names></name>; <name><surname>Kmiecik</surname><given-names>S.</given-names></name>
<article-title>Protein-peptide molecular
docking with large-scale
conformational changes: the p53-MDM2 interaction</article-title>. <source>Sci. Rep.</source>
<year>2016</year>, <volume>6</volume>, <fpage>37532</fpage><pub-id pub-id-type="doi">10.1038/srep37532</pub-id>.<pub-id pub-id-type="pmid">27905468</pub-id></mixed-citation></ref><ref id="ref20"><mixed-citation publication-type="journal" id="cit20"><name><surname>Audie</surname><given-names>J.</given-names></name>; <name><surname>Swanson</surname><given-names>J.</given-names></name>
<article-title>Recent work in the
development and application of protein-peptide
docking</article-title>. <source>Future Med. Chem.</source>
<year>2012</year>, <volume>4</volume> (<issue>12</issue>), <fpage>1619</fpage>&#x02013;<lpage>1644</lpage>. <pub-id pub-id-type="doi">10.4155/fmc.12.99</pub-id>.<pub-id pub-id-type="pmid">22917249</pub-id></mixed-citation></ref><ref id="ref21"><mixed-citation publication-type="journal" id="cit21"><name><surname>Allen</surname><given-names>S. E.</given-names></name>; <name><surname>Dokholyan</surname><given-names>N. V.</given-names></name>; <name><surname>Bowers</surname><given-names>A. A.</given-names></name>
<article-title>Dynamic docking of conformationally
constrained macrocycles: methods and applications</article-title>. <source>ACS Chem. Biol.</source>
<year>2016</year>, <volume>11</volume> (<issue>1</issue>), <fpage>10</fpage>&#x02013;<lpage>24</lpage>. <pub-id pub-id-type="doi">10.1021/acschembio.5b00663</pub-id>.<pub-id pub-id-type="pmid">26575401</pub-id></mixed-citation></ref><ref id="ref22"><mixed-citation publication-type="journal" id="cit22"><name><surname>Lee</surname><given-names>H.</given-names></name>; <name><surname>Heo</surname><given-names>L.</given-names></name>; <name><surname>Lee</surname><given-names>M. S.</given-names></name>; <name><surname>Seok</surname><given-names>C.</given-names></name>
<article-title>GalaxyPepDock: a protein-peptide
docking tool based on interaction similarity and energy optimization</article-title>. <source>Nucleic Acids Res.</source>
<year>2015</year>, <volume>43</volume> (<issue>W1</issue>), <fpage>W431</fpage>&#x02013;<lpage>W435</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkv495</pub-id>.<pub-id pub-id-type="pmid">25969449</pub-id></mixed-citation></ref><ref id="ref23"><mixed-citation publication-type="journal" id="cit23"><name><surname>Sedan</surname><given-names>Y.</given-names></name>; <name><surname>Marcu</surname><given-names>O.</given-names></name>; <name><surname>Lyskov</surname><given-names>S.</given-names></name>; <name><surname>Schueler-Furman</surname><given-names>O.</given-names></name>
<article-title>Peptiderive
server: derive peptide inhibitors from protein-protein interactions</article-title>. <source>Nucleic Acids Res.</source>
<year>2016</year>, <volume>44</volume> (<issue>W1</issue>), <fpage>W536</fpage>&#x02013;<lpage>W541</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkw385</pub-id>.<pub-id pub-id-type="pmid">27141963</pub-id></mixed-citation></ref><ref id="ref24"><mixed-citation publication-type="journal" id="cit24"><name><surname>Glas</surname><given-names>A.</given-names></name>; <name><surname>Bier</surname><given-names>D.</given-names></name>; <name><surname>Hahne</surname><given-names>G.</given-names></name>; <name><surname>Rademacher</surname><given-names>C.</given-names></name>; <name><surname>Ottmann</surname><given-names>C.</given-names></name>; <name><surname>Grossmann</surname><given-names>T. N.</given-names></name>
<article-title>Constrained
peptides with target-adapted
cross-links as inhibitors of a pathogenic protein-protein interaction</article-title>. <source>Angew. Chem., Int. Ed.</source>
<year>2014</year>, <volume>53</volume> (<issue>9</issue>), <fpage>2489</fpage>&#x02013;<lpage>2493</lpage>. <pub-id pub-id-type="doi">10.1002/anie.201310082</pub-id>.</mixed-citation></ref><ref id="ref25"><mixed-citation publication-type="journal" id="cit25"><name><surname>Glas</surname><given-names>A.</given-names></name>; <name><surname>Wamhoff</surname><given-names>E. C.</given-names></name>; <name><surname>Kr&#x000fc;ger</surname><given-names>D. M.</given-names></name>; <name><surname>Rademacher</surname><given-names>C.</given-names></name>; <name><surname>Grossmann</surname><given-names>T. N.</given-names></name>
<article-title>Increased conformational flexibility
of a macrocycle&#x02013;receptor
complex contributes to reduced dissociation rates</article-title>. <source>Chem. - Eur. J.</source>
<year>2017</year>, <pub-id pub-id-type="doi">10.1002/chem.201702776</pub-id>.</mixed-citation></ref><ref id="ref26"><mixed-citation publication-type="journal" id="cit26"><name><surname>Schafmeister</surname><given-names>C. E.</given-names></name>; <name><surname>Po</surname><given-names>J.</given-names></name>; <name><surname>Verdine</surname><given-names>G. L.</given-names></name>
<article-title>An all-hydrocarbon
cross-linking system for enhancing
the helicity and metabolic stability of peptides</article-title>. <source>J. Am. Chem. Soc.</source>
<year>2000</year>, <volume>122</volume> (<issue>24</issue>), <fpage>5891</fpage>&#x02013;<lpage>5892</lpage>. <pub-id pub-id-type="doi">10.1021/ja000563a</pub-id>.</mixed-citation></ref><ref id="ref27"><mixed-citation publication-type="journal" id="cit27"><name><surname>Cromm</surname><given-names>P. M.</given-names></name>; <name><surname>Spiegel</surname><given-names>J.</given-names></name>; <name><surname>Grossmann</surname><given-names>T. N.</given-names></name>
<article-title>Hydrocarbon
stapled peptides as modulators
of biological function</article-title>. <source>ACS Chem. Biol.</source>
<year>2015</year>, <volume>10</volume> (<issue>6</issue>), <fpage>1362</fpage>&#x02013;<lpage>1375</lpage>. <pub-id pub-id-type="doi">10.1021/cb501020r</pub-id>.<pub-id pub-id-type="pmid">25798993</pub-id></mixed-citation></ref><ref id="ref28"><mixed-citation publication-type="journal" id="cit28"><name><surname>Cromm</surname><given-names>P. M.</given-names></name>; <name><surname>Wallraven</surname><given-names>K.</given-names></name>; <name><surname>Glas</surname><given-names>A.</given-names></name>; <name><surname>Bier</surname><given-names>D.</given-names></name>; <name><surname>F&#x000fc;rstner</surname><given-names>A.</given-names></name>; <name><surname>Ottmann</surname><given-names>C.</given-names></name>; <name><surname>Grossmann</surname><given-names>T. N.</given-names></name>
<article-title>Constraining an irregular peptide
secondary structure through ring-closing alkyne metathesis</article-title>. <source>ChemBioChem</source>
<year>2016</year>, <volume>17</volume> (<issue>20</issue>), <fpage>1915</fpage>&#x02013;<lpage>1919</lpage>. <pub-id pub-id-type="doi">10.1002/cbic.201600362</pub-id>.<pub-id pub-id-type="pmid">27596722</pub-id></mixed-citation></ref><ref id="ref29"><mixed-citation publication-type="journal" id="cit29"><name><surname>Wang</surname><given-names>B. C.</given-names></name>; <name><surname>Yang</surname><given-names>H. Z.</given-names></name>; <name><surname>Liu</surname><given-names>Y. C.</given-names></name>; <name><surname>Jelinek</surname><given-names>T.</given-names></name>; <name><surname>Zhang</surname><given-names>L. X.</given-names></name>; <name><surname>Ruoslahti</surname><given-names>E.</given-names></name>; <name><surname>Fu</surname><given-names>H.</given-names></name>
<article-title>Isolation of high-affinity peptide
antagonists of 14&#x02013;3-3 proteins by phage display</article-title>. <source>Biochemistry</source>
<year>1999</year>, <volume>38</volume> (<issue>38</issue>), <fpage>12499</fpage>&#x02013;<lpage>12504</lpage>. <pub-id pub-id-type="doi">10.1021/bi991353h</pub-id>.<pub-id pub-id-type="pmid">10493820</pub-id></mixed-citation></ref><ref id="ref30"><mixed-citation publication-type="journal" id="cit30"><name><surname>Wu</surname><given-names>H.</given-names></name>; <name><surname>Ge</surname><given-names>J. Y.</given-names></name>; <name><surname>Yao</surname><given-names>S. Q.</given-names></name>
<article-title>Microarray-assisted
high-throughput
identification of a cell-permeable small-molecule binder of 14&#x02013;3-3
proteins</article-title>. <source>Angew. Chem., Int. Ed.</source>
<year>2010</year>, <volume>49</volume> (<issue>37</issue>), <fpage>6528</fpage>&#x02013;<lpage>6532</lpage>. <pub-id pub-id-type="doi">10.1002/anie.201003257</pub-id>.</mixed-citation></ref><ref id="ref31"><mixed-citation publication-type="journal" id="cit31"><name><surname>Arrendale</surname><given-names>A.</given-names></name>; <name><surname>Kim</surname><given-names>K.</given-names></name>; <name><surname>Choi</surname><given-names>J. Y.</given-names></name>; <name><surname>Li</surname><given-names>W.</given-names></name>; <name><surname>Geahlen</surname><given-names>R. L.</given-names></name>; <name><surname>Borch</surname><given-names>R. F.</given-names></name>
<article-title>Synthesis
of a phosphoserine mimetic prodrug with potent 14&#x02013;3-3 protein
inhibitory activity</article-title>. <source>Chem. Biol.</source>
<year>2012</year>, <volume>19</volume> (<issue>6</issue>), <fpage>764</fpage>&#x02013;<lpage>771</lpage>. <pub-id pub-id-type="doi">10.1016/j.chembiol.2012.05.011</pub-id>.<pub-id pub-id-type="pmid">22726690</pub-id></mixed-citation></ref><ref id="ref32"><mixed-citation publication-type="journal" id="cit32"><name><surname>Bier</surname><given-names>D.</given-names></name>; <name><surname>Rose</surname><given-names>R.</given-names></name>; <name><surname>Bravo-Rodriguez</surname><given-names>K.</given-names></name>; <name><surname>Bartel</surname><given-names>M.</given-names></name>; <name><surname>Ramirez-Anguita</surname><given-names>J. M.</given-names></name>; <name><surname>Dutt</surname><given-names>S.</given-names></name>; <name><surname>Wilch</surname><given-names>C.</given-names></name>; <name><surname>Klarner</surname><given-names>F. G.</given-names></name>; <name><surname>Sanchez-Garcia</surname><given-names>E.</given-names></name>; <name><surname>Schrader</surname><given-names>T.</given-names></name>; <name><surname>Ottmann</surname><given-names>C.</given-names></name>
<article-title>Molecular
tweezers modulate 14&#x02013;3-3
protein-protein interactions</article-title>. <source>Nat. Chem.</source>
<year>2013</year>, <volume>5</volume> (<issue>3</issue>), <fpage>234</fpage>&#x02013;<lpage>239</lpage>. <pub-id pub-id-type="doi">10.1038/nchem.1570</pub-id>.<pub-id pub-id-type="pmid">23422566</pub-id></mixed-citation></ref><ref id="ref33"><mixed-citation publication-type="journal" id="cit33"><name><surname>Thiel</surname><given-names>P.</given-names></name>; <name><surname>Roglin</surname><given-names>L.</given-names></name>; <name><surname>Meissner</surname><given-names>N.</given-names></name>; <name><surname>Hennig</surname><given-names>S.</given-names></name>; <name><surname>Kohlbacher</surname><given-names>O.</given-names></name>; <name><surname>Ottmann</surname><given-names>C.</given-names></name>
<article-title>Virtual screening and
experimental validation reveal
novel small-molecule inhibitors of 14&#x02013;3-3 protein-protein interactions</article-title>. <source>Chem. Commun.</source>
<year>2013</year>, <volume>49</volume> (<issue>76</issue>), <fpage>8468</fpage>&#x02013;<lpage>8470</lpage>. <pub-id pub-id-type="doi">10.1039/c3cc44612c</pub-id>.</mixed-citation></ref><ref id="ref34"><mixed-citation publication-type="journal" id="cit34"><name><surname>Milroy</surname><given-names>L. G.</given-names></name>; <name><surname>Bartel</surname><given-names>M.</given-names></name>; <name><surname>Henen</surname><given-names>M. A.</given-names></name>; <name><surname>Leysen</surname><given-names>S.</given-names></name>; <name><surname>Adriaans</surname><given-names>J. M. C.</given-names></name>; <name><surname>Brunsveld</surname><given-names>L.</given-names></name>; <name><surname>Landrieu</surname><given-names>I.</given-names></name>; <name><surname>Ottmann</surname><given-names>C.</given-names></name>
<article-title>Stabilizer-guided inhibition
of protein-protein interactions</article-title>. <source>Angew. Chem.,
Int. Ed.</source>
<year>2015</year>, <volume>54</volume> (<issue>52</issue>), <fpage>15720</fpage>&#x02013;<lpage>15724</lpage>. <pub-id pub-id-type="doi">10.1002/anie.201507976</pub-id>.</mixed-citation></ref><ref id="ref35"><mixed-citation publication-type="journal" id="cit35"><name><surname>Trott</surname><given-names>O.</given-names></name>; <name><surname>Olson</surname><given-names>A. J.</given-names></name>
<article-title>Software news and update AutoDock Vina: improving the
speed and accuracy of docking with a new scoring function, efficient
optimization, and multithreading</article-title>. <source>J. Comput.
Chem.</source>
<year>2010</year>, <volume>31</volume> (<issue>2</issue>), <fpage>455</fpage>&#x02013;<lpage>461</lpage>.<pub-id pub-id-type="pmid">19499576</pub-id></mixed-citation></ref><ref id="ref36"><mixed-citation publication-type="journal" id="cit36"><name><surname>Koch</surname><given-names>O.</given-names></name>; <name><surname>Jager</surname><given-names>T.</given-names></name>; <name><surname>Heller</surname><given-names>K.</given-names></name>; <name><surname>Khandavalli</surname><given-names>P. C.</given-names></name>; <name><surname>Pretzel</surname><given-names>J.</given-names></name>; <name><surname>Becker</surname><given-names>K.</given-names></name>; <name><surname>Flohe</surname><given-names>L.</given-names></name>; <name><surname>Selzer</surname><given-names>P. M.</given-names></name>
<article-title>Identification
of M-tuberculosis thioredoxin reductase inhibitors based on high-throughput
docking using constraints</article-title>. <source>J. Med. Chem.</source>
<year>2013</year>, <volume>56</volume> (<issue>12</issue>), <fpage>4849</fpage>&#x02013;<lpage>4859</lpage>. <pub-id pub-id-type="doi">10.1021/jm3015734</pub-id>.<pub-id pub-id-type="pmid">23676086</pub-id></mixed-citation></ref><ref id="ref37"><mixed-citation publication-type="journal" id="cit37"><name><surname>Kruger</surname><given-names>D.
M.</given-names></name>; <name><surname>Evers</surname><given-names>A.</given-names></name>
<article-title>Comparison
of structure- and ligand-based virtual screening protocols
considering hit list complementarity and enrichment factors</article-title>. <source>ChemMedChem</source>
<year>2010</year>, <volume>5</volume> (<issue>1</issue>), <fpage>148</fpage>&#x02013;<lpage>158</lpage>. <pub-id pub-id-type="doi">10.1002/cmdc.200900314</pub-id>.<pub-id pub-id-type="pmid">19908272</pub-id></mixed-citation></ref><ref id="ref38"><mixed-citation publication-type="journal" id="cit38"><name><surname>Mooij</surname><given-names>W. T. M.</given-names></name>; <name><surname>Verdonk</surname><given-names>M. L.</given-names></name>
<article-title>General and targeted statistical potentials for protein-ligand
interactions</article-title>. <source>Proteins: Struct., Funct., Genet.</source>
<year>2005</year>, <volume>61</volume> (<issue>2</issue>), <fpage>272</fpage>&#x02013;<lpage>287</lpage>. <pub-id pub-id-type="doi">10.1002/prot.20588</pub-id>.<pub-id pub-id-type="pmid">16106379</pub-id></mixed-citation></ref><ref id="ref39"><mixed-citation publication-type="journal" id="cit39"><name><surname>Eldridge</surname><given-names>M.
D.</given-names></name>; <name><surname>Murray</surname><given-names>C. W.</given-names></name>; <name><surname>Auton</surname><given-names>T. R.</given-names></name>; <name><surname>Paolini</surname><given-names>G. V.</given-names></name>; <name><surname>Mee</surname><given-names>R. P.</given-names></name>
<article-title>Empirical
scoring functions 0.1. The development of a fast empirical scoring
function to estimate the binding affinity of ligands in receptor complexes</article-title>. <source>J. Comput.-Aided Mol. Des.</source>
<year>1997</year>, <volume>11</volume> (<issue>5</issue>), <fpage>425</fpage>&#x02013;<lpage>445</lpage>. <pub-id pub-id-type="doi">10.1023/A:1007996124545</pub-id>.<pub-id pub-id-type="pmid">9385547</pub-id></mixed-citation></ref><ref id="ref40"><mixed-citation publication-type="journal" id="cit40"><name><surname>Jones</surname><given-names>G.</given-names></name>; <name><surname>Willett</surname><given-names>P.</given-names></name>; <name><surname>Glen</surname><given-names>R. C.</given-names></name>; <name><surname>Leach</surname><given-names>A. R.</given-names></name>; <name><surname>Taylor</surname><given-names>R.</given-names></name>
<article-title>Development
and validation of a genetic algorithm for flexible docking</article-title>. <source>J. Mol. Biol.</source>
<year>1997</year>, <volume>267</volume> (<issue>3</issue>), <fpage>727</fpage>&#x02013;<lpage>748</lpage>. <pub-id pub-id-type="doi">10.1006/jmbi.1996.0897</pub-id>.<pub-id pub-id-type="pmid">9126849</pub-id></mixed-citation></ref><ref id="ref41"><mixed-citation publication-type="journal" id="cit41"><name><surname>Kim</surname><given-names>Y. W.</given-names></name>; <name><surname>Grossmann</surname><given-names>T. N.</given-names></name>; <name><surname>Verdine</surname><given-names>G. L.</given-names></name>
<article-title>Synthesis of all-hydrocarbon stapled
alpha-helical peptides via ring-closing olefin metathesis</article-title>. <source>Nat. Protoc.</source>
<year>2011</year>, <volume>6</volume>, <fpage>761</fpage>&#x02013;<lpage>771</lpage>. <pub-id pub-id-type="doi">10.1038/nprot.2011.324</pub-id>.<pub-id pub-id-type="pmid">21637196</pub-id></mixed-citation></ref><ref id="ref42"><mixed-citation publication-type="journal" id="cit42"><name><surname>Ghaffari</surname><given-names>A.</given-names></name>; <name><surname>Li</surname><given-names>Y. Y.</given-names></name>; <name><surname>Kilani</surname><given-names>R. T.</given-names></name>; <name><surname>Ghahary</surname><given-names>A.</given-names></name>
<article-title>14&#x02013;3-3 sigma
associates with cell surface aminopeptidase N in the regulation of
matrix metalloproteinase-1</article-title>. <source>J. Cell Sci.</source>
<year>2010</year>, <volume>123</volume> (<issue>17</issue>), <fpage>2996</fpage>&#x02013;<lpage>3005</lpage>. <pub-id pub-id-type="doi">10.1242/jcs.069484</pub-id>.<pub-id pub-id-type="pmid">20699358</pub-id></mixed-citation></ref><ref id="ref43"><mixed-citation publication-type="journal" id="cit43"><name><surname>Nefla</surname><given-names>M.</given-names></name>; <name><surname>Sudre</surname><given-names>L.</given-names></name>; <name><surname>Denat</surname><given-names>G.</given-names></name>; <name><surname>Priam</surname><given-names>S.</given-names></name>; <name><surname>Andre-Leroux</surname><given-names>G.</given-names></name>; <name><surname>Berenbaum</surname><given-names>F.</given-names></name>; <name><surname>Jacques</surname><given-names>C.</given-names></name>
<article-title>The pro-inflammatory cytokine 14&#x02013;3-3
epsilon is a ligand of CD13 in cartilage</article-title>. <source>J.
Cell Sci.</source>
<year>2015</year>, <volume>128</volume> (<issue>17</issue>), <fpage>3250</fpage>&#x02013;<lpage>3262</lpage>. <pub-id pub-id-type="doi">10.1242/jcs.169573</pub-id>.<pub-id pub-id-type="pmid">26208633</pub-id></mixed-citation></ref><ref id="ref44"><mixed-citation publication-type="journal" id="cit44"><name><surname>Ghaffari</surname><given-names>A.</given-names></name>; <name><surname>Li</surname><given-names>Y. Y.</given-names></name>; <name><surname>Kilani</surname><given-names>R. T.</given-names></name>; <name><surname>Ghahary</surname><given-names>A.</given-names></name>
<article-title>14&#x02013;3-3 sigma
associates with cell surface aminopeptidase N in the regulation of
matrix metalloproteinase-1</article-title>. <source>J. Cell Sci.</source>
<year>2010</year>, <volume>123</volume> (<issue>17</issue>), <fpage>2996</fpage>&#x02013;<lpage>3005</lpage>. <pub-id pub-id-type="doi">10.1242/jcs.069484</pub-id>.<pub-id pub-id-type="pmid">20699358</pub-id></mixed-citation></ref><ref id="ref45"><mixed-citation publication-type="journal" id="cit45"><name><surname>Jiang</surname><given-names>W. G.</given-names></name>; <name><surname>Sanders</surname><given-names>A. J.</given-names></name>; <name><surname>Katoh</surname><given-names>M.</given-names></name>; <name><surname>Ungefroren</surname><given-names>H.</given-names></name>; <name><surname>Gieseler</surname><given-names>F.</given-names></name>; <name><surname>Prince</surname><given-names>M.</given-names></name>; <name><surname>Thompson</surname><given-names>S. K.</given-names></name>; <name><surname>Zollo</surname><given-names>M.</given-names></name>; <name><surname>Spano</surname><given-names>D.</given-names></name>; <name><surname>Dhawan</surname><given-names>P.</given-names></name>; <name><surname>Sliva</surname><given-names>D.</given-names></name>; <name><surname>Subbarayan</surname><given-names>P. R.</given-names></name>; <name><surname>Sarkar</surname><given-names>M.</given-names></name>; <name><surname>Honoki</surname><given-names>K.</given-names></name>; <name><surname>Fujii</surname><given-names>H.</given-names></name>; <name><surname>Georgakilas</surname><given-names>A. G.</given-names></name>; <name><surname>Amedei</surname><given-names>A.</given-names></name>; <name><surname>Niccolai</surname><given-names>E.</given-names></name>; <name><surname>Amin</surname><given-names>A.</given-names></name>; <name><surname>Ashraf</surname><given-names>S. S.</given-names></name>; <name><surname>Ye</surname><given-names>L.</given-names></name>; <name><surname>Helferich</surname><given-names>W. G.</given-names></name>; <name><surname>Yang</surname><given-names>X.</given-names></name>; <name><surname>Boosani</surname><given-names>C. S.</given-names></name>; <name><surname>Guha</surname><given-names>G.</given-names></name>; <name><surname>Ciriolo</surname><given-names>M. R.</given-names></name>; <name><surname>Aquilano</surname><given-names>K.</given-names></name>; <name><surname>Chen</surname><given-names>S.</given-names></name>; <name><surname>Azmi</surname><given-names>A. S.</given-names></name>; <name><surname>Keith</surname><given-names>W. N.</given-names></name>; <name><surname>Bilsland</surname><given-names>A.</given-names></name>; <name><surname>Bhakta</surname><given-names>D.</given-names></name>; <name><surname>Halicka</surname><given-names>D.</given-names></name>; <name><surname>Nowsheen</surname><given-names>S.</given-names></name>; <name><surname>Pantano</surname><given-names>F.</given-names></name>; <name><surname>Santini</surname><given-names>D.</given-names></name>
<article-title>Tissue invasion and
metastasis: Molecular, biological and clinical perspectives</article-title>. <source>Semin. Cancer Biol.</source>
<year>2015</year>, <volume>35</volume>, <fpage>S244</fpage>&#x02013;<lpage>S275</lpage>. <pub-id pub-id-type="doi">10.1016/j.semcancer.2015.03.008</pub-id>.<pub-id pub-id-type="pmid">25865774</pub-id></mixed-citation></ref><ref id="ref46"><mixed-citation publication-type="journal" id="cit46"><name><surname>Nagase</surname><given-names>H.</given-names></name>; <name><surname>Visse</surname><given-names>R.</given-names></name>; <name><surname>Murphy</surname><given-names>G.</given-names></name>
<article-title>Structure
and function of matrix
metalloproteinases and TIMPs</article-title>. <source>Cardiovasc. Res.</source>
<year>2006</year>, <volume>69</volume> (<issue>3</issue>), <fpage>562</fpage>&#x02013;<lpage>573</lpage>. <pub-id pub-id-type="doi">10.1016/j.cardiores.2005.12.002</pub-id>.<pub-id pub-id-type="pmid">16405877</pub-id></mixed-citation></ref><ref id="ref47"><mixed-citation publication-type="journal" id="cit47"><name><surname>Konttinen</surname><given-names>Y. T.</given-names></name>; <name><surname>Ainola</surname><given-names>M.</given-names></name>; <name><surname>Valleala</surname><given-names>H.</given-names></name>; <name><surname>Ma</surname><given-names>J.</given-names></name>; <name><surname>Ida</surname><given-names>H.</given-names></name>; <name><surname>Mandelin</surname><given-names>J.</given-names></name>; <name><surname>Kinne</surname><given-names>R. W.</given-names></name>; <name><surname>Santavirta</surname><given-names>S.</given-names></name>; <name><surname>Sorsa</surname><given-names>T.</given-names></name>; <name><surname>Lopez-Otin</surname><given-names>C.</given-names></name>; <name><surname>Takagi</surname><given-names>M.</given-names></name>
<article-title>Analysis of 16 different
matrix metalloproteinases (MMP-1 to MMP-20) in the synovial membrane:
different profiles in trauma and rheumatoid arthritis</article-title>. <source>Ann. Rheum. Dis.</source>
<year>1999</year>, <volume>58</volume> (<issue>11</issue>), <fpage>691</fpage>&#x02013;<lpage>697</lpage>. <pub-id pub-id-type="doi">10.1136/ard.58.11.691</pub-id>.<pub-id pub-id-type="pmid">10531073</pub-id></mixed-citation></ref><ref id="ref48"><mixed-citation publication-type="journal" id="cit48"><name><surname>Morris</surname><given-names>G. M.</given-names></name>; <name><surname>Huey</surname><given-names>R.</given-names></name>; <name><surname>Lindstrom</surname><given-names>W.</given-names></name>; <name><surname>Sanner</surname><given-names>M. F.</given-names></name>; <name><surname>Belew</surname><given-names>R. K.</given-names></name>; <name><surname>Goodsell</surname><given-names>D. S.</given-names></name>; <name><surname>Olson</surname><given-names>A. J.</given-names></name>
<article-title>AutoDock4
and AutoDockTools4: Automated
docking with selective receptor flexibility</article-title>. <source>J. Comput. Chem.</source>
<year>2009</year>, <volume>30</volume> (<issue>16</issue>), <fpage>2785</fpage>&#x02013;<lpage>2791</lpage>. <pub-id pub-id-type="doi">10.1002/jcc.21256</pub-id>.<pub-id pub-id-type="pmid">19399780</pub-id></mixed-citation></ref><ref id="ref49"><mixed-citation publication-type="book" id="cit49"><source>Maestro</source>, version 9.7; <publisher-name>Schrodinger LLC</publisher-name>: <publisher-loc>New York</publisher-loc>, <year>2014</year>.</mixed-citation></ref></ref-list></back></article>